20 research outputs found

    Use of Mini-Sprinklers to Strip Trichloroethylene and Tetrachloroethylene from Contaminated Ground Water

    Get PDF
    Three low-volume mini-sprinklers were tested for their efficacy to strip trichloroethylene (TCE) and tetrachloroethylene (PCE) from water. Deionized water spiked with TCE and PCE as pumped for approximately 1 h at 0.19 to 0.21 MPa (28 to 30 lb in-2) through a mini-sprinkler supported on top of a 1.8-m-tall riser. Water was collected in collection vessels at 0.61 and 1.22 m above the ground on support columns that were spaced at 0.61-m intervals from the riser base, and samples were composited per height and distance from the riser. Overall, air-stripping reduced dissolved concentrations of TCE and PCE by 99.1 to 100 and 96.9 to 100%, respectively, from mean influent dissolved concentrations of 466 to 1675 μg L-1 TCE and 206 to 940 μg L-1, respectively, over a 1-h test period. Mini-sprinklers offer the advantages of (i) easy setup in series that can be used on practically any terrain; (ii) operation over a long period of time that does not threaten aquifer depletion; (iii) use in small or confined aquifers in which the capacity is too low to support large irrigation or purging systems; and (iv) use in forests in which the small, low-impact droplets of the mini-sprinklers do not damage bark and in which tress can help manage (via evapotranspiration) excess water waste

    Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes

    Get PDF
    Background Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. Results Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4+ T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4+ T cell responses were enhanced by IFNα subtypes. Conclusions Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4+ T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines

    Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Get PDF
    This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.</p
    corecore